Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Agios Anticipates PK Deficiency Diagnosis Ramp-Up After Pyrukynd Approval

Reimbursement Challenges

Executive Summary

The company hopes to grow the current diagnostic rate from 30% to 70% over two to five years. “Optimal reimbursement” for mitapivat will likely take a year, with Medicare/Medicaid lagging.

You may also be interested in...



Finance Watch: PTC Secures Up To $1bn In Funding From Blackstone

Public Company Edition: PTC will get $350m up front as part of an initial $500m commitment. Also, while Biohaven and Vaxcyte launched traditional follow-on offerings, Recursion and Agios took the private placement and royalty sale routes, while others revealed job cuts and other strategic updates. 

Novo Nordisk’s Forma Buy Builds On Foothold In Rare Blood Disorders

Novo's head of rare disease Ludovic Helfgott talked to Scrip about the $1.1bn acquisition and expansion into sickle cell disease.

Fueled By Connections: Making It Happen In Rare Disease

Agios’s Sarah Gheuens talks to In Vivo about the responsibility of providing new therapies to rare disease populations, building trust with historically underserved communities, and why she loves working with small molecules.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145924

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel